Global Initiative for Asthma (GINA) guideline: achieving optimal asthma control in children aged 6-11 years

Submitted: July 5, 2023
Accepted: August 28, 2023
Published: September 7, 2023
Abstract Views: 1449
PDF: 56
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

The Global Initiative for Asthma (GINA) 2021 guidelines for asthma have been set forth with some alterations in step 3, for children from the 6-11-year-old age group. The low-dose inhaled corticosteroid (ICS)-long-acting β-agonist (LABA), very low-dose formoterol-ICS, medium-dose ICS, and ICS-leukotriene receptor antagonist (LTRA) combination were recommended in the guideline. We organized this study to draw an effective comparison between these three combinations of controller therapies in the pediatric population. A retrospective study was conducted at the Aga Khan University Hospital (Karachi, Pakistan), which enrolled 114 children aged 6-11 years old from July 2021 to December 2022. These children were admitted with asthma exacerbations and were discharged on controller medications as per GINA guidelines on step 3 for control of asthma for 3 months. They were then followed for re-admission within 30 days of discharge, number of emergency room (ER) visits with asthma exacerbations for 1 year, number of admissions with asthma, including high dependency unit and pediatric intensive care unit (PICU) admissions, and length of stay per admission for all admissions in the subsequent year. The pulmonary function test was done at the 1-week follow-up in the clinic after discharge and at the 3-month visit post-discharge. A total of 114 pediatric patients from 6 to 11 years old were enrolled in the study period, out of which 36 (31.57%), 33 (28.9%), and 34 (29.82%) patients were categorized into ICS-LABA, ICS, and ICS-LTRA groups, respectively. ER visits were significantly low in the ICS-LABA group, followed by the ICS-LRTA group and then the ICS group (1.75±0.96 versus 2.93±1.412 versus 3.11±1.21, p<0.001). Similar statistically significant results were observed on the average number of admissions per year (1.52±1.02 versus 1.96±0.84 versus 2.06±1.07, p=0.047) and the number of patients needing PICU (13.88% versus 26.47% versus 39.39%, p=0.034) in these groups, respectively. ICS-LABA group patients had the best values of the forced expiratory volume in one second (FEV1) and FEV1/forced vital capacity ratio after pulmonary function tests at 3 months follow-up, followed by ICS-LTRA and ICS group. Amongst the three options for regimens for children managed at step 3 on GINA 2021 guidelines, ICS-LABA therapy helps attain optimal patient outcomes and lung functions in children with asthma, followed by ICS-LTRA and ICS group, respectively.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

Davitte J, DeBarmore B, Hinds D, et al. Asthma control among treated US asthma patients in Practice Fusion’s electronic medical record research database. NP J Prim Care Respir Med 2023;33:17.
World Health Organization. Asthma. Available from: https://www.who.int/news-room/fact-sheets/detail/asthma. Accessed on: 06/04/2023.
Global Initiative for Asthma (GINA). Available from: https://ginasthma.org/about-us/. Accessed on: 06/04/2023.
Calhoun WJ, Chupp GL. The new era of add-on asthma treatments: where do we stand? Allergy Asthma Clin Immunol 2022;18:42.
Reddel HK, Bacharier LB, Bateman ED, et al. Global initiative for asthma strategy 2021: executive summary and rationale for key changes. Eur Respir J 2022;59:2102730.
Fuhlbrigge A, Peden D, Apter AJ, et al. Asthma outcomes: exacerbations. J Allergy Clin Immunol 2012;129:S34-48.
Dharmage SC, Perret JL, Custovic A. Epidemiology of asthma in children and adults. Front Pediatr 2019;7:246.
Barnes PJ. Scientific rationale for inhaled combination therapy with long-acting beta1-agonists and corticosteroids. Eur Respir J 2002;19:182-91.
Barnes PJ. Clinical outcome of adding long-acting beta-agonists to inhaled corticosteroids. Respir Med 2001;95:S12-6.
Tesse R, Borrelli G, Mongelli G, et al. Treating pediatric asthma according guidelines. Front Pediatr 2018;6:234.
Choi J, Azmat CE. Leukotriene receptor antagonists. Treasure Island, FL, USA: StatPearls; 2023.
Adams NP, Bestall JC, Jones P, et al. Fluticasone at different doses for chronic asthma in adults and children. Cochrane Database Syst Rev 2008;2008:CD003534.
FitzGerald JM, Boulet LP, McIvor RA, et al. Asthma control in Canada remains suboptimal: the Reality of Asthma Control (TRAC) study. Can Respir J 2006;13:253-9.
Vaessen-Verberne AA, van den Berg NJ, van Nierop JC, et al. Combination therapy salmeterol/fluticasone versus doubling dose of fluticasone in children with asthma. Am J Respir Crit Care Med 2010;182:1221-7.
Al-Turki A, Salvator A, Bai S, Sheikh SI. Comparison of two therapies on asthma control in children. Pediatr Allergy Immunol Pulmonol 2020;33:127-35.
Rodrigo GJ, Moral VP, Marcos LG, Castro-Rodriguez JA. Safety of regular use of long-acting beta agonists as monotherapy or added to inhaled corticosteroids in asthma: a systematic review. Pulmon Pharmcol Ther 2009;22:9-19.
Malone R, LaForce C, Nimmagadda S, et al. The safety of twice-daily treatment with fluticasone propionate and salmeterol in pediatric patients with persistent asthma. Ann Allergy Asthma Immunol 2005;95:66-71.
Xia Y, Kelton CM, Xue L, et al. Safety of long-acting beta agonists and inhaled corticosteroids in children and adolescents with asthma. Ther Adv Drug Saf 2013;4:254-63.
Chauhan BF, Chartrand C, Ni Chroinin M, et al. Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children. Cochrane Database Syst Rev 2015;2015:CD007949.
Chauhan BF, Ducharme FM. Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children. Cochrane Database Syst Rev 2012;2012:CD002314.
Chauhan BF, Ducharme FM. Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma. Cochrane Database Syst Rev 2014;2014:CD003137.
Chauhan BF, Jeyaraman MM, Singh Mann A, et al. Addition of anti-leukotriene agents to inhaled corticosteroids for adults and adolescents with persistent asthma. Cochrane Database Syst Rev 2017;3:CD010347.

Ethics Approval

The study was approved by the Institutional Review Board of the Aga Khan University Hospital, Karachi (protocol PED-18471).

How to Cite

Aziz, Danish Abdul, Muhammad Aqib Sajjad, and Ameema Asad. 2023. “Global Initiative for Asthma (GINA) Guideline: Achieving Optimal Asthma Control in Children Aged 6-11 Years”. Monaldi Archives for Chest Disease 94 (3). https://doi.org/10.4081/monaldi.2023.2701.

Similar Articles

<< < 2 3 4 5 6 7 8 9 10 11 > >> 

You may also start an advanced similarity search for this article.